Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Defence Therapeutics Inc (DTC.CN)

Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 59,103
  • Shares Outstanding, K 54,725
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,193 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +18.63%
on 03/11/25
1.4000 -13.57%
on 03/05/25
+0.0300 (+2.54%)
since 02/27/25
3-Month
0.6000 +101.67%
on 01/14/25
1.6600 -27.11%
on 02/19/25
+0.5700 (+89.06%)
since 12/27/24
52-Week
0.4800 +152.08%
on 09/19/24
1.7500 -30.86%
on 04/01/24
-0.4900 (-28.82%)
since 03/27/24

Most Recent Stories

More News
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer

Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million

Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025

Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Fortifies Patent Portfolio

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Provides Update on Delivery of AGSM Proxy Materials

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)
Defence Announces Closing of Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 0.9964 (+7.30%)
DTC.CN : 1.2100 (+12.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Key Turning Points

3rd Resistance Point 1.1300
2nd Resistance Point 1.1200
1st Resistance Point 1.1000
Last Price 1.2100
1st Support Level 1.0700
2nd Support Level 1.0600
3rd Support Level 1.0400

See More

52-Week High 1.7500
Fibonacci 61.8% 1.2649
Last Price 1.2100
Fibonacci 50% 1.1150
Fibonacci 38.2% 0.9651
52-Week Low 0.4800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar